Literature DB >> 9303357

Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R.

K Tanaka1, H Inoue, H Miki, E Masuda, M Kitaichi, K Komaki, T Uyama, Y Monden.   

Abstract

We have demonstrated the expression of thyrotropin receptor (TSH-R) in thyroid neoplasms (13 adenomas, 21 papillary carcinomas, two follicular carcinomas) and adjacent normal thyroid using the monoclonal antibody against human TSH-R and have also demonstrated a relationship between prognostic scores and the expression of TSH-R. Among the adenomas, eight showed an intensity similar to that of normal thyroid and five showed a higher intensity than normal. Two tumours exhibited heterogeneous distribution of TSH-R. Among the papillary carcinomas, seven showed similar intensity to normal tissue and four showed higher intensity and ten showed weaker intensity. Eight tumours showed heterogeneous distribution of the stain. Among the follicular carcinomas, one showed similar intensity to normal tissue and the other exhibited weaker intensity. Both cases showed homogeneous distribution of TSH-R. The adenomas never showed a weaker intensity than normal thyroid, but various intensities of TSH-R occurred in differentiated carcinomas. There was no significant relationship between the clinical data and the signal intensity in the adenomas. Among the papillary carcinomas, however, the group with weaker intensity had significantly poorer prognostic scores than the other two groups. Thus, we assume that low TSH-R may be expressed by the clinically high-risk group of patients with papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303357      PMCID: PMC2228017          DOI: 10.1038/bjc.1997.431

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

Review 1.  The thyrotropin receptor and the regulation of thyrocyte function and growth.

Authors:  G Vassart; J E Dumont
Journal:  Endocr Rev       Date:  1992-08       Impact factor: 19.871

2.  Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization.

Authors:  K Tanaka; H Inoue; H Miki; K Komaki; Y Monden
Journal:  Clin Endocrinol (Oxf)       Date:  1996-03       Impact factor: 3.478

3.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

4.  Long-term impact of initial and surgical therapy on papillary and follicular thyroid cancer.

Authors:  L J DeGroot
Journal:  Am J Med       Date:  1994-12       Impact factor: 4.965

5.  Impairment of the TSH signal transduction system in human thyroid carcinoma cells.

Authors:  H Kimura; S Yamashita; H Namba; T Usa; K Fujiyama; M Tsuruta; N Yokoyama; M Izumi; S Nagataki
Journal:  Exp Cell Res       Date:  1992-12       Impact factor: 3.905

6.  The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma.

Authors:  B Cady; K Cohn; R L Rossi; C E Sedgwick; W A Meissner; J Werber; R S Gelman
Journal:  Surgery       Date:  1983-12       Impact factor: 3.982

7.  Risk factor analysis in differentiated thyroid cancer.

Authors:  B Cady; C E Sedgwick; W A Meissner; M S Wool; F A Salzman; J Werber
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

8.  Overexpression of the intact thyrotropin receptor in a human thyroid carcinoma cell line.

Authors:  H Namba; S Yamashita; T Usa; H Kimura; N Yokoyama; M Izumi; S Nagataki
Journal:  Endocrinology       Date:  1993-02       Impact factor: 4.736

9.  Prognosis in thyroid carcinoma.

Authors:  K O Franssila
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues.

Authors:  K Ohta; T Endo; T Onaya
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

View more
  4 in total

1.  Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery.

Authors:  Katsuhiro Tanaka; Hiroshi Sonoo
Journal:  Surg Today       Date:  2011-12-17       Impact factor: 2.549

2.  Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.

Authors:  Jeong Won Park; Li Zhao; Mark C Willingham; Sheue-Yann Cheng
Journal:  Mol Carcinog       Date:  2016-06-14       Impact factor: 4.784

3.  Loss of Rap1GAP in papillary thyroid cancer.

Authors:  Anoma Nellore; Karolina Paziana; Changqing Ma; Oxana M Tsygankova; Yan Wang; Kanchan Puttaswamy; Ammarah U Iqbal; Susanna R Franks; Yu Lv; Andrea B Troxel; Michael D Feldman; Judy L Meinkoth; Marcia S Brose
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

4.  Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma.

Authors:  Katsuhiro Tanaka; Hiroshi Sonoo; Wataru Saito; Yusuke Ohta; Toshiro Shimo; Mai Sohda; Yutaka Yamamoto; Junichi Kurebayashi
Journal:  ISRN Endocrinol       Date:  2011-03-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.